Flerie publishes Annual report 2024

Regulatory

Flerie AB (publ) has published its 2024 Annual report on www.flerie.com.

In the Annual report, CEO Ted Fjällman, comments on the challenging year for biotech and pharma, Flerie’s performance, and how the successful IPO reinforced our active ownership model and ability to drive innovation.

”Being public Flerie now offers exposure and liquidity to a mostly private portfolio of highly innovative life science companies.” says Ted Fjällman, CEO

Read more in our Annual report 2024 on www.flerie.com.

For more information:

Ted Fjällman, CEO
Email: ir@flerie.com

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

This information is information that Flerie AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-27 08:00 CET.

Attachments
Flerie AB Annual Report 2024

Documents